WO2022119854A8 - Compounds for the treatment of sars - Google Patents
Compounds for the treatment of sars Download PDFInfo
- Publication number
- WO2022119854A8 WO2022119854A8 PCT/US2021/061269 US2021061269W WO2022119854A8 WO 2022119854 A8 WO2022119854 A8 WO 2022119854A8 US 2021061269 W US2021061269 W US 2021061269W WO 2022119854 A8 WO2022119854 A8 WO 2022119854A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sars
- compounds
- treatment
- covid
- cov
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- FTQWRYSLUYAIRQ-UHFFFAOYSA-N n-[(octadecanoylamino)methyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCNC(=O)CCCCCCCCCCCCCCCCC FTQWRYSLUYAIRQ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Bis-amide inhibitors of SARS-CoV-2 (COVID) and methods of using them to treat a severe acute respiratory syndrome.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063120101P | 2020-12-01 | 2020-12-01 | |
| US63/120,101 | 2020-12-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2022119854A1 WO2022119854A1 (en) | 2022-06-09 |
| WO2022119854A8 true WO2022119854A8 (en) | 2023-06-01 |
Family
ID=81853525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2021/061269 WO2022119854A1 (en) | 2020-12-01 | 2021-11-30 | Compounds for the treatment of sars |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2022119854A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202322793A (en) | 2021-11-02 | 2023-06-16 | 香港商英科智能有限公司 | Sars-cov-2 inhibitors for treating coronavirus infections |
-
2021
- 2021-11-30 WO PCT/US2021/061269 patent/WO2022119854A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022119854A1 (en) | 2022-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022119858A8 (en) | Compounds for the treatment of sars | |
| MX2022013081A (en) | Compounds for the treatment of sars. | |
| PH12021500005A1 (en) | Sulfonimidamide compounds as inhibitors of interleukin-1 activity | |
| GEP20237519B (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| MX2023005747A (en) | Gcn2 and perk kinase inhibitors and methods of use thereof. | |
| MX2022001697A (en) | Pyrrolopyridine-aniline compounds for treatment of dermal disorders. | |
| MX2022001004A (en) | Enzyme inhibitors. | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| MX2021016049A (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer. | |
| WO2021158635A8 (en) | Anti-viral compositions and methods of use | |
| CR20230362A (en) | Cdk2 inhibitors and methods of using the same | |
| WO2022119854A8 (en) | Compounds for the treatment of sars | |
| CR20220280A (en) | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor | |
| MX2022000811A (en) | Enzyme inhibitors. | |
| MX2023006651A (en) | Treatment of hemophilia with fitusiran. | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
| MX2022007457A (en) | Methods of treating coronavirus. | |
| MX2022014303A (en) | Compounds for the treatment of sars. | |
| WO2023122260A3 (en) | Inhibitors of sars-cov-2 | |
| MX2022004270A (en) | Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency. | |
| WO2020109233A3 (en) | Trmt2a inhibitors for use in the treatment of polyglutamine diseases | |
| WO2020086954A3 (en) | Treatments for charcot-marie-tooth disease | |
| WO2020055544A3 (en) | Method for treating pancreatic cancer | |
| MX2020010231A (en) | A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor. | |
| AU2018258588A8 (en) | Inhibitors of TRIM33 and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21901336 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21901336 Country of ref document: EP Kind code of ref document: A1 |